Figure 2

In silico immune simulation results of the ASFV vaccine construct (solid lines) compared with adjuvant alone (dash line) administered at 0-4th-8th week intervals. Graphs: (A) immunoglobulin production and antigen clearance. (B) Helper T-lymphocyte populations. (C) B-lymphocyte populations.